Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 2/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540240 | 0.81 | HTR7 (0.49) | HTR7CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3694813 | 0.80 | CYP2A6 (0.44) | SYKCYP2C19CYP1A2MAPTMALT1 | |
| SCHEMBL6141318 | 0.79 | NOS1 (0.50) | SYKNOS1NOS2CYP2C19CYP1A2 | |
| SCHEMBL5915750 | 0.79 | HTR7 (0.53) | HTR7CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5538035 | 0.78 | HTR7 (0.45) | HTR7CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31023263 | 0.78 | HTR7 (0.45) | HTR7CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12218215 | 0.77 | EGFR (0.47) | HTR7CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9101071 | 0.77 | HTR7 (0.52) | HTR7CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7285414 | 0.76 | HTR7 (0.51) | HTR7CYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11696738 | 0.76 | MAPT (0.71) | SYKNOS1NOS2CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7642367-B2 | Diamino-functional chalcones | LICA PHARMACEUTICALS A/S (DK) | 2010-01-05 | — | — | US | disclosed |
| US-20060235073-A1 | Diamino-functional chalcones | LICA PHARMACEUTICALS A/S (DK) | 2006-10-19 | — | — | US | disclosed |
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1671948-A1 | CINNAMOYL COMPOUND AND USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211680-A1 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | COL2A1, COL1A1, COL14A1 | HTR7 4410/4885SYK 4643/4885NOS1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.